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Autoimmune Mechanism and 
Recurrence Risk in Graves’ Disease
Vasudha Bakshi and Gollapalli Rajeev Kumar
Abstract
Graves’ disease (GD) is an autoimmune thyroid disorder where autoantibodies  
are produced against TSH (Thyroid Stimulating Hormone) receptor causing thyro-
toxicosis. It is characterized by goiter, ophthalmopathy, and occasionally pretibial 
myxedema. The autoimmune mechanism causing disease is not well understood 
and it is complex. It involves multifactorial etiology involving environmental and 
genetic factors. Smoking and positive family history contributing to the develop-
ment of GD. GD can be diagnosed based on the clinical manifestation and dem-
onstrating low concentration of TSHs, high TRab (Thyroid Stimulating Hormone 
receptor autoantibodies), and high FT4 (Free thyroxine) concentration. Current 
treatment options aimed at stable restoration of euthyroidism by following different 
modalities of suppressing thyroid gland using antithyroid drugs, removing/ablating 
thyroid gland by surgery, and radioactive iodine treatment with iodine- 131.
Keywords: Graves’ disease, Thyroid Stimulating Hormone, Thyroid Stimulating 
Hormone receptor autoantibodies, Free thyroxine
1. Introduction
In this particular, Graves’ disease (GD) an autoimmune disorder, caused by 
excessive secretion of the glandular thyroid hormones by the thyroid follicles, 
which is related to the progressive hyperthyroidism condition. It is found to be the 
main cause of hyperthyroidism. The annual incidence has been reported of about 
14–50 cases per 100,000 populations [1]. The disease may affect at any age and the 
incidence increases with age. The peak incidence of GD is between 30 and 50 years. 
It is generally accepted that younger patients have a severe immune system disorder 
where GD is predominantly found [1]. Few studies showed that younger patients 
are having poorer responses to ATD and poor prognosis with recurrent risk [2–4]. 
The lifetime risk of getting Graves’ disease is roughly 6 times higher in women than 
in men [1]. The exact mechanism of affecting the different gender is not known 
but believed to be associated with different sex hormones. Females are being 
affected more and the strongest risk factor contributed to the development of GD is 
estrogen. Estrogen influences B- cell functioning and regulates the immune system 
[5]. In GD patients, elevated estradiol relates to TRAb (TSH receptor antibody) 
positivity [6]. The risk of recurrence of GD after the withdrawal of the anti-thyroid 
drugs (ATG) is majorly seen in male GD patients [7, 8]. Large goiter with severe 
immune disorders and genetic aspects are associated with the development of GD 
in males. Genetic factors associated with GD are cytotoxic T-associated lymphocyte 
factor-4 (CTLA4) rs231779 and rs231775, especially Thyroglobulin (Tg) and TSHR 
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polymorphisms are linked with relapse in GD after the withdrawal of ATD. At four 
weeks following the completion of a randomized tobacco trial of ATD, the TRAb 
level was significantly higher in smokers than in nonsmokers [9–11]. Smoking 
promotes elevated levels of TRAb contributed to the development of GD. A number 
of factors recognized against GD includes stress, sex and sex hormones, pregnancy, 
infection, other autoimmune diseases, iodine and other potential environmental 
factors such as radiation have been recognized against Graves’ disease. The resulting 
breakdown in thyroid tolerance would lead to errors in multiple protective immune 
mechanisms. It is noted that sera of Graves’s patients may contain the “predominant 
Hashimoto” thyroglobulin (Tg) and thyroid peroxidase antibodies (TPO Abs). 
Antibodies toward Hashimoto bind to the TSH receptor while, rather than pro-
moting TSH action, block the growth of TSH action during illness and have seen 
positive results throughout the thyroid condition of Graves’ disease [12].
2. Clinical features of graves’ disease condition
Symptoms of hyperthyroidism associated with thyrotoxicosis are nervousness, 
overactivity, insomnia, palpitations, mental confusion, weight loss and prominent 
signs of thyrotoxicosis are tachycardia, atrial fibrillation, hyperreflexia systemic 
hypertension, warm moist skin, hyperactivity, and tremors. The clinical features 
predominantly observed in GD are orbithopathy, pretibial myxedema, and goiter.
The pathogenesis of ophthalmopathy includes the immune response to a TSH 
receptor–like protein in orbital connective tissue initiates cytokine formation fur-
ther promoting production by orbital fibroblasts of hydrophilic glycosaminoglycan, 
resulting in high osmotic pressure, fluid accumulation, and clinical ophthalmopa-
thy. Eye muscle antigens include the flavoprotein (Fp) subunit of mitochondrial 
succinate dehydrogenase, G2s and the FOX P1 protein, a winged helix transcription 
factor, and their respective antibodies are clinically useful markers in the diagno-
sis of GD. The respective roles of the connective tissue response and eye muscle 
antibodies involved in the pathogenesis are under investigation.
3. Pathogenesis
Autoimmune thyroid diseases are the most prevalent organ- specific which 
includes Graves’ disease (GD) and Hashimoto’s Thyroiditis (HT). The hyperactivity 
of the thyroid gland is due to the production of thyroid stimulating antibodies (auto-
antibodies) and are known to recognize and activate thyroid stimulating hormone 
receptor. The autoantibodies produced by TSHR increase the growth and functioning 
to thyroid follicular cells resulting over production of T3 and T4. It has been suggested 
by the studies that a genetic clonal lack of suppressor T cells may be responsible for 
the inappropriate and unregulated production of TSH receptor antibody [13].
3.1 Autoimmunity mechanism
The pathological process involved in Graves’ disease is similar to other auto-
immune disease but a unique aspect found in the majority of patients is TSHR 
antibodies which cannot be found in normal individuals. The characterization 
of the autoimmunity process includes a lymphocytic infiltrate seen at the target 
organ and the presence of antigen-reactive T and B cells against thyroid antigens. 
As in all autoimmune diseases it is observed when self-tolerance is broken; T cells 
identify self-antigens, and B cells produce antibodies targeting host cells. Many cell 
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self-specific T cells escape thymic deletion; however, additional mechanisms like 
clonal anergy and peripheral suppression normally prevent reactions to auto anti-
gen. B cells which recognize a specific cell auto antigen in the lymphoid organs are 
taken into T lymphocyte areas; B lymphocytes normally kill by apoptosis if they are 
not activated by T available cells while B lymphocytes, binding soluble self-antigen, 
are anergised; they down- regulate expression of membrane IgM and live for a short 
period. B cells are inactivated by T-cells available for support. An additional B cell 
tolerance mechanism includes allelic exclusion and clonal ignorance in receptor and 
autoreactive B cell receptor (BCRs).
3.2 The thyroid antigens
3.2.1 Tg and TPO
Thyroglobulin (Tg) is 660 kDa, a dimeric glycoprotein secreted by the fol-
licular cells of the thyroid gland and acts as a substrate for the synthesis of T3 and 
T4. Besides, it stores an inactive form of thyroid hormone and iodine in the lumen 
of the thyroid follicle. The antibodies produced in response to Tg induce massive 
destruction of the thyroid gland but few studies propose to show high levels of 
Tg do not perse induce antibody production. Thyroid hormones are synthesized 
on the Tg with the help of thyroid peroxidase (TPO). TPO is an enzyme Anti-
thyroglobulin antibody (ATA) and TPO- specific T cells are often found in GD 
patients. Tg antibodies recognize the confirmation of a large fragment of Tg [14]. 
These are directed against the same epitopes which are mainly observed in GD. 
Antibodies against TPO are involved in complement/antibody-mediated cell 
toxicity and target toward conformational epitopes.
3.2.2 GD auto antigen and TSH receptor antibodies
The auto antigen which is mainly expressed in Graves’ disease is thyroid stimu-
lating hormone receptor (TSHR). It is a G protein coupled receptor with 7 trans 
membrane spanning domains expressed in thyroid gland but also in adipose cells, 
fibroblasts, bone cells including heart cells [15]. Binding to circulating TSH, a 
G-Protein signal activates adenylcyclase cascade events and intracellular levels of c 
AMP increases. Rise in c AMP activates all the functional activities of thyroid cell 
which includes iodine pumping; synthesis of thyroglobulin, iodination, endocyto-
sis, and proteolysis; activity involving thyroid peroxidases; and hormone release. 
Literatures suggest that there may be a shedding of the TSHR ectodomain [16–18] 
even though it has not been confirmed in vivo.
The presence of TSHR-Antibodies (TSHR-Abs) [19] is the most unusual feature 
of most GD-patients. The early analysis of TSHR-Abs [20] represents the most 
accurate definition of their features, which resulted by analysis of monoclonal 
antibodies to the TSHR from various sources, including human, mouse and ham-
ster: mouse and hamster antibodies are secondary to TSHR [21–23]. Three types of 
TSHR-Ab are identified among autoimmune-thyroid patients and similar diseases 
are observed in immunized rodents; stimulating, blocking, and so-called “neutral.” 
TSHR-Abs that has proved to be beyond neutral in their biological activity has 
been characteristic of the TSHR ectodomain’s cleavage. Stimulating Antibodies 
(Stimulating Abs) induce cAMP production and inhibit any simultaneous activa-
tion of the thyroid function that bind to naturally conformed TSHR. TSHR block-
ing antibodies, its main bioactivity of this is to prevent TSH receptor binding in a 
manner that may cause thyroid problems, and also it act as weak TSH agonists. Such 
blocking antibodies depend on conformation, and others are very similar to the 
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decreased TSHR antigen and/or linear peptides. At the end, neutral TSHR antibod-
ies may not prevent or stimulate cAMP production or TSH adhering. Neutral TSHR-
antibodies bind only to linear epitopes and are targeted against the “unique region” 
located in receptor among specific amino acids 316–366 [24]. In GD patients, 
the presence of different ratios with high-affinity TSHR-Abs contributes to the 
clinical phenotype. Therefore, a function-based classification of these antibodies 
appears more relevant than their ability or failure to influence the binding of TSHs 
or cAMPs.
3.3 Different epitopes of TSHR Abs
3.3.1 Monoclonal antibodies against TSHR
Any monoclonal antibody raised to TSHR protein or antigen includes synthe-
sized peptides and recombinant ones, that have been shown to be neutralizing 
in mechanism. Only natural intact TSH receptors or genetic immune are used to 
stimulate thyroid-stimulating antibodies and establish an animal hyperthyroidism 
model [25–28]. Monoclonal antibodies, such as MS-1, have been raised in hamsters 
utilizing rare B cells that secrete TSHR-enhancing antibodies [29]. Rodents and 
humans have been used to identify blocking and neutral monoclonal antibod-
ies (mAbs).
3.3.2 Stimulating TSHR-Ab epitopes
Part of the TSHR ectodomain has also been crystallized with the support of 
appropriate stimulating monoclonal fragment TSHR Fab bound in situ [30]. Many 
amino acids have a large section of the concave surface of the TSHR ectodomain 
that has been identified as important for antibody binding, in the leucin-rich repeat 
region (LRR). Reviewing recent studies particularly at conformational epitopes 
using mass spectrometry [29] have shown that epitopes exist outside the LRR for 
blocking and stimulating monoclonal antibodies. The prominent region exist at N 
terminal region of the extracellular domain (ECD) has been well demonstrated and 
also at the residues in the “hinge” region [31].
3.3.3 Blocking TSHR-Ab epitopes
TSHR antibodies block epitopes are widely distributed compared to stimulat-
ing antibodies. Thus, blocking TSHR monoclonal antibodies (TSHR-mAbs) have 
been shown to have binding affinities to independent or confirmational epitopes 
[32]. In patients with GD or HT, TSHR autoantibodies showed themselves to 
compete in N-terminal TSHR beta subunit (aa382–415), with a blocking TSHR-
mAb. Blocking hypothyroid antibodies therefore is heterogeneous in nature and 
this repertoire of anti-bodies involves multiple epitopes. Crystallization and 
modeling of human and mouse blocking TSHR Abs attempting to block and these 
TSHR-Abs strongly proposed that the N-terminal and the leucine-rich binding are 
linked [33, 34].
3.3.4 Cleavage TSHR-Ab epitopes
Peptide binding (ELISA) and the monoclonal competition of antibodies in 
patients with Graves’s disease is shown throughout cleavage (aaa 316–366) (com-
petitive inhibition assay by FACS). The tissues of the TSHR are strongly related. The 
main linear epitopes in animal GD models are known in the area of cleavage [35]. 
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Such antibodies are not competitive to TSH-borne binding in the cleaved area and 
are therefore often called “neutral.”
3.4 TSHR-mAb induced signal transduction
Through the stimulation of agonist, TSH and TSHR-Abs the TSH receptor seems 
to be active and enhanced. Intracellular signal transmissions spread through clas-
sical GPCR effector proteins with the Gαq and Gαs interaction with the recipient 
directly.
Docking Gαs into the activated receptor results in an increased adenylatecyclasis 
activity generated by the cAMP, direct activation of protein kinase A (PKA) and 
cAMP element-binding protein (CREB). Gαq docking involves PI3 and DAG forma-
tion and further activation of Ca2+ and protein kinase C (PKC). Enables Erk1/2 and 
p90RSK subsequently. Stimulating TSH-mAb has shown to act in a dose-dependent 
and time-dependent manner via the Gαq-PKC-Akt cascade, and the rat thyroid 
model (FrTL-5) was found to be relevant on PKA signaling [36, 37]. Monoclonal 
antibodies, which are frequently detected by point-of-care tests, were also demon-
strated to activate non classical TSH receptor pathways, though this was reported as 
only a few of the studies have shown this. Certain neutral antibodies are not found 
to increase cAMP, but could signal by means of Akt, c-Raf/ERK1/2/p90RSK, PKC, 
and PKA/CREB [37].
3.5 Apoptosis in GD
Apoptosis is absolutely essential for the development of the aggressive immune 
system. The initial theories about thyroidectomy-induced autoimmunity postulated 
that antibody and T cell-mediated destruction of the thyroid contributed to the 
death of thyrocytes. In the ensuing years, it is discovered that apoptosis had a part 
in GD [38]. Apoptosis provided a new insight into autoimmune target destruction, 
further implying the participation in possible pathogenesis of thyroid autoimmu-
nity from death-controlled receptors and cytokine-related apoptotic pathways. An 
abnormally increased level of CD4(+) regulatory T cells break host immune toler-
ance and initiate T-reg apoptosis [39] and, in this way, foster abnormal T-mediated 
immune activation in patients with GD. Bcl-2 regulatory protein family is recently 
linked to the pathogenesis of GD [40] looked at apoptotic proteins, and observed a 
relation to the expression of the Bcl-2 regulatory family in the thyroid follicular cells 
in GD [41]. Furthermore, the researchers suggested that an increase in apoptotic 
molecules (Fas/FasL and caspase 8) are present on T and B lymphocytes in GD and 
HT patients, demonstrating involvement in GD pathogenesis. It is clear to describe 
in apoptosis, death receptors/ligands play a regulatory role, but caspase-indepen-
dent mechanisms can also coexist and contribute to GD thyroid cell death.
3.6 Apoptosis and thyrocyte oxidative stress induced by TSHR antibodies
The induction of cell proliferation via stimulating- monoclonal antibodies 
(mAbs) shown in thyrocyte stimulation studies with TSHR-mAbs that have been 
conducted with cAMP. Some neutral monoclonal antibodies (mAbs) have been 
identified as stimulating multiple stress signals and apoptosis induced. These 
antibodies are responsible for activation of multiple oncogenes, including p53, 
p73 and Reactive oxygen species (ROS). In addition, endoplasmic reticulum stress 
protein (gp98) is induced and the expression of heat shock proteins (p27 and p107), 
hemaoxygenase (HO) and superoxide dismutase (SOD) is further activated and 
supported.These data support stress signals in the thyroid cells of Graves’ disease. 
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A morphologic staining (annexin V and propidium iodide) and a quantitative flow 
cytometry test [42] confirmed the cell death caused by apoptosis, and is likely to 
confirm the previously described histological evidence that thyroid tissue apoptosis 
is found in GD patients. These observations have revealed that stress signaling 
cascades have been involved although oxidative stress alone or cell-specific signal-
ing molecules induced such apoptosis remain unclear. These results also indicated 
the ability of neutral TSHR monoclonal antibodies (TSHR-mAbs), which is known 
to activate inborn and bystander immune reactivity via DNA release from apoptotic 
cells [43], to aggravate the local infiltration in a thyroid. This same phenomenon 
may be associated with graves’ orbitopathy as these cells were abundantly expressed 
by activation-induced fibroblast death.
3.7 Humoral immunity
The GD Rodents have shown humoral immunity against other TSHR-
immunized antigens, unless outbred animals like hamsters have been used, to show 
intrathyroid infiltrate. This implies that GD is an intricate genetic disorder, usually 
associated with autoimmune thyroiditis. AITD is not known for the presence of 
pendrin antibodies, sodium iodides symporters [44, 45], thyroxine, triiodothyronin 
[46], tubulin, megalin, calmo-modulin and DNA, or DNA-related proteins [47–49]. 
The IGF-1 receptor is widespread in B cells and in fibroblast from GD patients, 
although over-expressed. In activation of the thyrocyte, synergism between 
antibodies to TSHR and the IGF-1 receptor was suggested. That requires further 
research as TSH and IGF-1 or insulin are commonly known to induce proliferation 
of thyroid cells.
4. Diagnosis
Diagnosis of GD is complex and difficult. The combined effect of several 
symptoms and symptoms leads the doctor to suspect the thyroid irregularity. 
Comprehensive history such as intake or exposure to iodine, drugs, thyroid and 
autoimmune history and physical exam, vital signs such as pulse rate measure-
ment, blood pressure measurement, respiratory and body weight. Moreover, the 
presence or absence of a thyroid tenderness, symmetry and nodularity should also 
be evaluated; pulmonary, cardiac and neuromuscular function and the presence of 
eye signs or pretibial myxedema. Because hyperthyroidism is frequently associated 
with low or undetectable levels of TSH, it is an easy biochemical diagnosis to make 
if thyrotoxicosis is found. T4 and T3 are usually high, but are relatively higher in 
GD serumT3 than T4. The T4 and T3 concentration levels are usually high. In mild 
forms of hyperthyroidism and during earliest phases of DG only serum T3 levels 
can be enhanced (T3 toxicosis). The removal of the lid, anxiety, an increase in neck 
volume, signs of involvement with the eye and the history of autoimmune disease in 
the family also distinguish GD from other types of hyperthyroidism (e.g., toxin goi-
ter, toxic adenoma) (e.g., silent or subacute thyroiditis, exogenous thyroid hormone 
use). Serum measurement of the TSH-receptor automatic antibody (TRAb) helps 
confirm diagnosis. New bioassays for the thyroid stimulant immunoglobulin (TSI) 
especially aid in the measurement of TSI’s ability to increase the intracellular cAMP 
level by detecting stimulating antibodies. Radioactive Iodine uptaking (RAIU), 
despite a clinical examination, thyroid function evaluation and TRAb detection 
should only be carried out when the diagnosis is unclear. The pattern for iodine 
uptake in GD is diffuse if no coexisting nodules or fibrosis do not occur. Technetium 
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99 can be of assistance. Increased color Doppler flow supports thyroid hyperactiv-
ity diagnosis. In case of thyroid nodularity in the neck or in a thyroid scintigram, 
thyroid scan must be conducted.
5. The factors that influence the recurrence in GD patients
5.1 Biochemical parameter
The severity is linked to recurrence risk in ATD-treated GD patients. Partly the 
biochemical parameters help to determine the seriousness of GD. The parametric 
increase of serum T3, which is affected by increased intrathyroid type 1 deiodinase 
activity, is significant in untreated GD. Independent GD factors influenced free 
thyroxine-to-free triiodothyronine ratio (FT3 andFT4) is predictive for the ATD 
treatment outcome for patients with GD. Hyperthyroidism symptoms observed 
after the treatment with beta-blockers. Patients with a higher T3/FT3 or FT3/
T4 serum ratio have been found to be more at recurrence, requiring a longer and 
more additional dose in the treatment. The risk of relapsed treatment is increased 
for patients with a higher serum T3 and FT3/FT4 ratio. When a patient has a high 
T3/T4 ratio, therapy should be continued for at least one year after the ATD has 
been removed. Serum thyroid-stimulating hormone (TSH) should be measured. 
However, as it is known, the thyroid hormone has a negative feed-back influence 
on the TSH. Thus, prior research has established that drug discontinuation is 
associated with elevated levels of TSH. These findings suggest that treatment with 
a prolonged ATD may be indicated for GD patients who do not normalize their 
thyroid-stimulating hormone levels quickly.
5.2 Immune parameters
The GD is the result of hyper-activation by TRAb of the TSH receptor in fol-
licular thyroid cells. In approximately 95% of newly diagnosed GD patients, TRAb 
is positive and higher TRAb levels are indicative of serious immune disorder. Recent 
times have demonstrated TRAb as a helpful and qualitative prognostic indicator 
for ATD therapy. At the time of GD diagnosis, patients with high TRAb levels 
had a considerably higher recurrence risk, while TRAb patients were often more 
likely to get long-term recovery. Switching from positive to negative TRAb in GD 
patients involves a reduced immune disorder after ATD therapy. In the prognosis of 
GD patients, TRAb levels were also observed at ATD withdrawal. Recurrence risk 
was noted to be increased in TRAb-positive GD during the time of drug discon-
tinuation. New assays can be used to distinguish the stimulating (stimulating) 
and blocking (disturbing) effects of medications on antigen responses. Thyroid 
stimulating antibodies (TSAb) antibodies are found to be predominant in GD 
patients. Recently, the value of TRAb for patients on GD treatments for recurrence 
risk with prediction has been shown to be greater than that of GD, particularly 
TSAb. GD patients with thyroiditis from Hashimoto appear to be remission after 
Hashimoto’s thyroiditis due to advanced harm. The prevalence of peroxidase/
peroxidase antibodies is highest in people with Hashimoto’s thyroiditis. Few studies 
have analyzed whether the existence of Thyroid peroxidase antibodies (TPOAb) 
and Thyroglobulin antibodies (TgAb) autoantibodies is linked to the risk of a 
subsequent relapse in those with GD. People with GD may also show low TPOAb 
and TgAb levels, and in such cases, the clinical and laboratory findings are not 




A major clinical manifestation found in GD patients is the large goiter. Previous 
studies show a large predictor of increased risk of recurrence in GD patients after 
the removal of ATD, goiter size. Findings from 5 years of trail follow-up have shown 
that the rate of remission for normal or mild-goiter patients is higher than for large-
goiter patients. GD patients with significantly lower goiter sizes tend to have higher 
rates of remission after ATD treatment. Enlarged goiter size at the time of GD 
diagnosis and drug withdrawal is associated with a higher recurrence risk of GD.
5.4 Graves’ orbitopathy
At the time of diagnosis of GD, Graves’ orbitopathy is observed in 35% of 
patients. Sometimes, the presence of the Graves orbitopathy indicated that the 
immune system gets worsen. Previous studies show that the risk of GD recurrence 
after withdrawal of ATD in patients with Graves’ orbitopathy is higher [38]. An 
Eckstein et al. study even found that GD patients with severe Graves’ orbitopathy 
only received a 7% remission rate. Although the recurrence rate is higher, the ATD 
treatment remains a preferred therapeutic option for GD patients with orbitopathy 
of Graves because Graves’s orbitopathy improves as well as a steady eutyroid status 
achieved and reduces inflammatory markers of the TRAb. Recent studies have dem-
onstrated that the continuous low dose of ATD has helped to improve GD disease in 
Graves orbitopathy patients.
5.5 Genetic factors
Genetic factors plays a key role in the pathogenesis of GD and increase the 
risk of recurrence to the development of GD. Several studies supports both 
cytotoxic T-lymphocyte-associated factor 4 (CTLA4) rs231775 and rs231779 
polymorphisms were strongly associated with recurrence of GD even after ATD 
withdrawal in Asians, while there is no association in Caucasians for developing 
GD. In Caucasian patients with GD, the recurrence risk after ATD withdrawal 
was observed with the polymorphisms of HLA DQA2, HLA DRB1∗03, and HLA 
DQB1∗02. The HLA region majorly contains immune response genes and tHLA 
polymorphisms might also influence the outcome of GD patients by regulating the 
immune system.
5.6 Environmental factors
GD starts with some environmental factors in the predisposed genetic associa-
tion in individuals. Stress is one of the important environmental considerations, 
and a majority of the studies have supported the association between stress and 
recurrence in GD patients after ATD therapy. The overall stress score for large life 
events was significantly higher in the recurrence group in a prospective study that 
examined the recurrence risk of GD in patients than in the remission. Another trial 
showed that the recurrence group was more stressful than the remission patients, 
and that the total number of stressful events is linked to the number of the recur-
rence. Psychosocial stress is an important part of a stressful event. It is worth 
mentioning. Previous trials showed that the risk of GD recurrence is higher than 
that of GD patients without such a disease for patients with psychiatric disorders as 
depression and hypochondriasis. Therefore, reducing stress is an essential way of 
improving the prognosis of ATD-treated GD patients. Another ecological factor is 
iodine intake.
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The synthesis of the thyroid hormone is based on Iodine. Increased content 
of iodine in thyrocytes has promoted degradation of ATD and reduced uptake of 
ATD. The supplementation of iodine increased the GD recurrence rate. After ATD 
withdrawal hyperthyroidism in euthyroid GD patients arose when pharmaceutical 
doses of iodine were taken. Epidemiologic studies have shown, however, that in 
iodine-adequate countries, recurrence rates in GD patients do not exceed those in 
iodine-deficient areas following ATD withdrawal.
6. Conclusion
Autoimmunity is a collection of heterogeneous disorders which is controlled 
by complex genetic and environmental factors. In GD, the prominent antigen 
responsible is TSHR and the studies of extra thyroidal TSHR expression in different 
variety of cell types and immune cells has added to the complexity of the disease 
and also introduced a variety of potential new mechanisms that may be involved. 
A common approach of GD is that TSHR-Abs promote the disease by enhancing 
thyroid antigen expression. Precision medicine’s promise is still important in the 
future. The chapter has personalized diagnostic and therapeutic approaches will 
encompass both a patient’s genomic makeup and their environmental factors.
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